시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 비후성 심근병증 치료 시장 보고서(2025년)
Hypertrophic Cardiomyopathy Treatment Global Market Report 2025
상품코드 : 1691906
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,265,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,056,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,846,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 비후성 심근병증 치료 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 예측 기간의 주요 동향에는 조기 개입, 환자 중심의 케어, 웨어러블 의료 기술, 건강 공평성에 대한 대처 등이 있습니다.

비만률 증가는 당분간 비후성 심근병증 치료 시장 확대의 기폭제로서 작용할 것으로 예측됩니다. 2022년 3월, 세계보건기구(WHO)는 비만이 세계 10억 명 이상에 영향을 미치고 있으며, 그 내역은 성인 6억 5,000만명, 청년 3억 4,000만명, 소아 3,900만명이라고 하는 보고서를 발표했습니다. 또한 2025년까지 1억 6,700만 명이 과체중과 비만과 관련된 건강과제에 직면할 것으로 예측되고 있습니다.

환자의 의식 향상과 교육 프로그램 증가가 향후 몇 년간의 비후성 심근병증(HCM) 치료 시장의 성장을 견인할 것으로 예상됩니다. 이러한 프로그램은 중요한 정보를 제공해 건강 유지 및 증진, 필요한 이해와 사고방식, 스킬을 향상시키고 환자의 행동에 영향을 미치는 것을 목적으로 하고 있습니다. 이 질환에 대한 계몽 및 교육 프로그램의 시작은 조기 진단 및 조기 치료를 촉진하여 위험을 완화하는 데 도움이 됩니다. 2024년 9월 GOV.UK는 영국 성인의 고등교육 및 기능훈련 참가자가 0.9% 증가해 162만 7,320명이 되었다고 보고했습니다. 또한, 성인 교육 및 훈련 참가자는 4.6% 증가해, 863,790명에 달했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Hypertrophic cardiomyopathy (HCM) is a heart condition characterized by the thickening of the heart muscle, primarily affecting the left ventricle, the major pumping chamber. This thickening often occurs at the septum, which is the muscular wall separating the left and right sides of the heart. The treatment approach for hypertrophic cardiomyopathy is personalized, and specific recommendations can vary depending on individual cases.

The primary categories of hypertrophic cardiomyopathy treatment include obstructive hypertrophic cardiomyopathy treatment and non-obstructive hypertrophic cardiomyopathy treatment. Obstructive hypertrophic cardiomyopathy (HCM) is a condition in which the thickening of the muscular wall (septum) between the two lower chambers of the heart (ventricles) can block the flow of blood out of the heart. Diagnosis of hypertrophic cardiomyopathy involves various tests, including chest X-rays, echocardiograms, electrocardiograms (ECGs), treadmill stress tests, cardiac catheterization, genetic testing or screening, cardiac MRI, cardiac CT scans, and blood tests. Treatment can take various forms, such as medication, surgically implanted devices, nonsurgical procedures, and surgery. These treatments are applied in various healthcare settings, including hospitals, research institutes, and specialty clinics.

The hypertrophic cardiomyopathy treatment market research report is one of a series of new reports from The Business Research Company that provides hypertrophic cardiomyopathy treatment market statistics, including hypertrophic cardiomyopathy treatment industry global market size, regional shares, competitors with a hypertrophic cardiomyopathy treatment market share, detailed hypertrophic cardiomyopathy treatment market segments, market trends and opportunities and any further data you may need to thrive in the hypertrophic cardiomyopathy treatment industry. This hypertrophic cardiomyopathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypertrophic cardiomyopathy treatment market size has grown steadily in recent years. It will grow from $1.37 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to advances in diagnostic technologies, drug therapies, surgical interventions, clinical guidelines.

The hypertrophic cardiomyopathy treatment market size is expected to see steady growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, personalized medicine, regenerative medicine. Major trends in the forecast period include early intervention, patient-centered care, wearable health technology, health equity initiatives.

The growth in obesity rates is anticipated to act as a catalyst for the expansion of the hypertrophic cardiomyopathy treatment market in the foreseeable future. Obesity is characterized by an abnormal accumulation of excess body fat that can have detrimental effects on one's health. It often results from an imbalance between calorie intake and expenditure through physical activity. Notably, obesity is a common occurrence in individuals with hypertrophic cardiomyopathy (HCM) and is believed to influence the phenotype of the condition. For instance, in March 2022, the World Health Organization released a report indicating that obesity affects over one billion individuals worldwide, encompassing 650 million adults, 340 million adolescents, and 39 million children. Furthermore, it is projected that by 2025, an additional 167 million people will face health challenges associated with being overweight or obese. Consequently, the upsurge in obesity rates is poised to be a driving force behind the hypertrophic cardiomyopathy treatment market.

Rising patient awareness and education programs are expected to drive the growth of the hypertrophic cardiomyopathy (HCM) treatment market in the coming years. These programs aim to influence patient behavior by improving understanding, mindset, and skills necessary to maintain or improve health through the provision of crucial information. Hypertrophic cardiomyopathy is a rare genetic disorder that often goes undiagnosed due to a lack of awareness. The launch of awareness and education programs for this disease helps reduce risks by promoting early diagnosis and treatment. For example, in September 2024, GOV.UK reported a 0.9% increase in adult participation in further education and skills in the UK, with 1,627,320 participants. Moreover, participation in adult education and training rose by 4.6%, reaching 863,790. Therefore, the growing emphasis on patient awareness and education is propelling the hypertrophic cardiomyopathy treatment market.

Market players operating in the hypertrophic cardiomyopathy treatment domain are actively engaged in pioneering drug development endeavors to uphold their standing within the market. This pursuit of drug development and innovation serves to advance our understanding of disease mechanisms and accelerate the emergence of novel treatment modalities. A case in point is the announcement made by Bristol Myers Squibb Co. in April 2022, whereby the US Food and Drug Administration (FDA) granted approval for Camzyos (mavacamten), designed for the treatment of individuals exhibiting symptoms of obstructive hypertrophic cardiomyopathy (obstructive HCM) classified under New York Heart Association (NYHA) class II-III. Camzyos represents a groundbreaking allosteric and reversible cardiac myosin inhibitor engineered to address the underlying pathology of obstructive HCM. With this green light from the FDA, cardiologists in the United States now have access to a new pharmaceutical option for eligible patients, offering a therapeutic approach that directly targets the fundamental pathophysiology of the disease.

In March 2023, Viz.ai, in collaboration with Bristol-Myers Squibb Company, embarked on an endeavor to detect and triage patients requiring further evaluation for hypertrophic cardiomyopathy (HCM) detection through the utilization of an artificial intelligence (AI) algorithm and the Viz HCM provider workflow software. This partnership between Viz and Bristol Myers Squibb seeks to ensure that underdiagnosed and underserved HCM patients receive the necessary care promptly, courtesy of proficient healthcare providers. The comprehensive offering includes a mobile-based ECG viewer, AI-based alerts for timely intervention, and communication capabilities designed to enhance cardiac care coordination. Bristol Myers Squibb Co. is a pharmaceutical enterprise headquartered in the United States that specializes in the treatment of hypertrophic cardiomyopathy (HCM).

Major companies operating in the hypertrophic cardiomyopathy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., Sun Pharmaceutical Industries Ltd., PerkinElmer Inc., Cipla Ltd., Aurobindo Pharma Ltd., Bio-Rad Laboratories Inc., Covance Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo International Inc., Lupin Limited, Zydus Lifesciences Limited, XyloCor Therapeutics Inc., Cytokinetics Inc., Santhera Pharmaceuticals Holding AG, DiNAQOR AG, Correvio Pharma Corp, Cardurion Pharmaceuticals Inc.

North America was the largest region in the hypertrophic cardiomyopathy treatment market in 2024. The regions covered in hypertrophic cardiomyopathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypertrophic cardiomyopathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hypertrophic cardiomyopathy treatment market consists of revenues earned by entities by providing services such as surgical myectomy, implantable defibrillator and septal alcohol ablation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy market also includes the sales of medications such as calcium channel blockers, heart rhythm drugs and blood thinners. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypertrophic Cardiomyopathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypertrophic cardiomyopathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hypertrophic cardiomyopathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypertrophic cardiomyopathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Hypertrophic Cardiomyopathy Treatment Market Characteristics

3. Hypertrophic Cardiomyopathy Treatment Market Trends And Strategies

4. Hypertrophic Cardiomyopathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hypertrophic Cardiomyopathy Treatment Growth Analysis And Strategic Analysis Framework

6. Hypertrophic Cardiomyopathy Treatment Market Segmentation

7. Hypertrophic Cardiomyopathy Treatment Market Regional And Country Analysis

8. Asia-Pacific Hypertrophic Cardiomyopathy Treatment Market

9. China Hypertrophic Cardiomyopathy Treatment Market

10. India Hypertrophic Cardiomyopathy Treatment Market

11. Japan Hypertrophic Cardiomyopathy Treatment Market

12. Australia Hypertrophic Cardiomyopathy Treatment Market

13. Indonesia Hypertrophic Cardiomyopathy Treatment Market

14. South Korea Hypertrophic Cardiomyopathy Treatment Market

15. Western Europe Hypertrophic Cardiomyopathy Treatment Market

16. UK Hypertrophic Cardiomyopathy Treatment Market

17. Germany Hypertrophic Cardiomyopathy Treatment Market

18. France Hypertrophic Cardiomyopathy Treatment Market

19. Italy Hypertrophic Cardiomyopathy Treatment Market

20. Spain Hypertrophic Cardiomyopathy Treatment Market

21. Eastern Europe Hypertrophic Cardiomyopathy Treatment Market

22. Russia Hypertrophic Cardiomyopathy Treatment Market

23. North America Hypertrophic Cardiomyopathy Treatment Market

24. USA Hypertrophic Cardiomyopathy Treatment Market

25. Canada Hypertrophic Cardiomyopathy Treatment Market

26. South America Hypertrophic Cardiomyopathy Treatment Market

27. Brazil Hypertrophic Cardiomyopathy Treatment Market

28. Middle East Hypertrophic Cardiomyopathy Treatment Market

29. Africa Hypertrophic Cardiomyopathy Treatment Market

30. Hypertrophic Cardiomyopathy Treatment Market Competitive Landscape And Company Profiles

31. Hypertrophic Cardiomyopathy Treatment Market Other Major And Innovative Companies

32. Global Hypertrophic Cardiomyopathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy Treatment Market

34. Recent Developments In The Hypertrophic Cardiomyopathy Treatment Market

35. Hypertrophic Cardiomyopathy Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기